Main Article Content
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic inflammatory autoimmune illnesses that
affect the quality of life for millions of people worldwide. Despite the availability of a variety of therapeutic
alternatives, there is a continuing unmet demand for effective medicines with improved safety profiles. The
Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is important in immune
signalling and has emerged as a possible therapeutic target for RA and PsA.
Tofacitinib has been shown in clinical studies to be effective in lowering disease activity, increasing physical
function, and preventing radiographic progression in people with RA and PsA. Furthermore, to facitinib has a
favourable safety profile, with controllable side events, however long-term safety data are still being gathered.
Tofacitinib is administered orally rather than intravenously, providing for increased patient comfort and
Conclusion: The JAK-STAT pathway is an important target in the treatment of RA and PsA, and tofacitinib,
a JAK inhibitor, has emerged as a viable therapeutic option for both disorders.